Results 71 to 80 of about 3,300,951 (351)

By dawn or dusk—how circadian timing rewrites bacterial infection outcomes

FEBS Letters, EarlyView.
The circadian clock shapes immune function, yet its influence on infection outcomes is only beginning to be understood. This review highlights how circadian timing alters host responses to the bacterial pathogens Salmonella enterica, Listeria monocytogenes, and Streptococcus pneumoniae revealing that the effectiveness of immune defense depends not only
Devons Mo, Catherine S. Palmer, Jacqueline M. Kimmey   +2 more
wiley   +1 more source

Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi

Frontiers in Immunology, 2020
Chagas disease caused by the protozoan parasite Trypanosoma cruzi is endemic in 21 Latin American countries and the southern United States and now is spreading into several other countries due to migration.
Natacha Cerny, Natacha Cerny, Augusto Ernesto Bivona, Augusto Ernesto Bivona, Andrés Sanchez Alberti, Andrés Sanchez Alberti, Sebastián Nicolás Trinitario, Sebastián Nicolás Trinitario, Celina Morales, Alejandro Cardoso Landaburu, Alejandro Cardoso Landaburu, Silvia Inés Cazorla, Silvia Inés Cazorla, Emilio Luis Malchiodi, Emilio Luis Malchiodi   +14 more
doaj   +1 more source

Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed

Frontiers in Immunology, 2021
Advances in high-throughput sequencing have revolutionized the manner with which we can study T cell responses. We describe a woman who received a human papillomavirus (HPV) therapeutic vaccine called PepCan, and experienced complete resolution of her ...
Takeo Shibata, Takeo Shibata, Sumit Shah, Teresa Evans, Hannah Coleman, Benjamin J. Lieblong, Horace J. Spencer, Charles M. Quick, Toshiyuki Sasagawa, Owen W. Stephens, Erich Peterson, Donald Johann, Yong-Chen Lu, Mayumi Nakagawa   +13 more
doaj   +1 more source

A Toll for lupus [PDF]

, 2005
Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity against chromatin, e.g., in systemic lupus erythematosus (SLE ...
Anders HJ, H-J Anders, Stacey KJ
core   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination

Vaccines, 2020
We discuss here some of the key immunological elements that are at the crossroads and need to be combined to develop a potent therapeutic HIV-1 vaccine.
Nabila Seddiki, Florence Picard, Léa Dupaty, Yves Lévy, Véronique Godot   +4 more
doaj   +1 more source

Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]

, 2014
Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin, Clark, Aaron J, Fakurnejad, Shayan, Ivan, Michael E, James, Charles D, Oh, Taemin, Parsa, Andrew T, Safaee, Michael, Sayegh, Eli T, Sun, Matthew Z   +9 more
core   +2 more sources

Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections [PDF]

, 2021
Background. Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of cancer.
Ahlén, G, Frelin, L, Jagya, N, Johansson, M, Maravelia, P, Meuleman, Philip, Ni, Y, Pasetto, A, Pater, L, Pérez, NC, Sällberg, M, Urban, S, Verch, G, Verhoye, Lieven   +13 more
core   +1 more source

Therapeutic Human Papillomavirus Vaccination

Public Health Genomics, 2009
Despite impressive progress in prevention and therapy of premalignant and malignant dysplasia the worldwide burden of cancer is relatively unchanged. Supplementation of the therapeutic arsenal by immunotherapeutic methods would have the potential to make a significant impact.
Andreas E, Albers, Andreas M, Kaufmann
openaire   +2 more sources

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)

PLoS ONE, 2018
Context Current drugs for chronic hepatitis B therapy have a poor efficacy in terms of post-treatment sustained viral suppression and generate important side effects during and after therapy.
Mamun Al Mahtab, S. M. Akbar, J. Aguilar, G. Guillén, E. Penton, Á. Tuero, O. Yoshida, Y. Hiasa, M. Onji   +8 more
semanticscholar   +1 more source